Easier Biosimilar Approval: Fewer Studies, Faster Access.
This act aims to simplify the approval process for biosimilar drugs, which are more affordable alternatives to expensive biological medicines. This could lead to citizens gaining faster access to necessary treatments and potentially lower healthcare costs, as fewer studies will be required to bring these drugs to market.
Key points
Fewer required studies: The act eliminates the need for certain studies assessing the risks of alternating or switching between biosimilar and reference products.
Faster drug access: Streamlined procedures may accelerate the availability of more affordable alternatives, increasing treatment accessibility.
Potential savings: Increased competition and faster introduction of biosimilars could lead to lower treatment costs for patients and the healthcare system.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.